… approved antiplatelet drugs include a narrow therapeutic window and limited efficacy. An
overview of the current Food and Drug Administration (FDA)-approved antiplatelet therapies as …

… to the clinical development of newer and more potent antiplatelet … new antiplatelet drugs
in the setting of ACS and PCI, including the most recent advances on newly approved agents …

… has led to the development of newer and more potent antiplatelet agents. The objective of the
… approved antiplatelet agents in the setting of ACS and PCI, as well as on emerging agents …

… Aspirin remains the "gold standard" antiplatelet agent, largely because of its … antiplatelet
agents. In contrast to aspirin, the initial use of which was largely empirical, these newer agents …

… several promising new antiplatelet agents as potential additions or alternatives to standard
therapy. The … Antiplatelet therapy is essential to the treatment of patients who are undergoing …

… Though many new approaches to develop newer agents are being looked into, but still,
aspirin is and will continue to enjoy the mainstay therapy status for the anti-platelet action, in the …

… targets and their known pathological and physiological roles in healthy or diseased
vasculature, the scientific basis for their selection and inhibition by existing agents, and new …

… of dual antiplatelet therapy with thienopyridine agents should be used after acute coronary
syndromes. Guidelines recommend at least 1 month of dual antiplatelet therapy after insertion …

… there is continuous need for more effective and safer antiplatelet agents. Conventional …
antiplatelet agents under development. In addition to this wealth of novel antiplatelet therapy, new …

… With the preponderance of platelets in arterial thrombi, antiplatelet therapy has been the
cornerstone for prevention and treatment of atherothrombosis (Figure 2). In contrast, …